At a glance
Effects
- Pain relief (moderate–severe): Reduces moderate to severe acute and chronic pain via combined opioid receptor activation and monoamine reuptake inhibition [1][2].
- Sedation / drowsiness: CNS depression produces feelings of drowsiness or calm; can impair driving and coordination [3][8].
- Mood alteration: Serotonin/norepinephrine activity can produce mild anxiolytic or mood-lifting effects, contributing to misuse potential [6][9].
- Constipation: Common opioid-class effect via gut mu-receptor activation; often occurs with regular use [3].
- Nausea / vomiting: Among the most frequently reported side effects, particularly on initiation [3].
Opioid analgesic / SNRI (dual-action)
DEA Schedule IV controlled substance
~6–7 hours (parent); extended in hepatic/renal impairment
Oral (tablet/capsule); IV in clinical settings
Peak plasma ~2 hours (immediate-release)
About Tramadol
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Tramadol is a centrally-acting synthetic opioid analgesic with a dual mechanism of action, used for the management of moderate to severe pain in adults [1][2]. It is classified as a Schedule IV controlled substance in the United States and is marketed under brand names including Ultram and Tramal [3][8].
How it works
Tramadol works through two complementary pathways [1][2]: (1) It binds to mu-opioid receptors in the brain — primarily via its active metabolite O-desmethyltramadol (M1), which has much higher opioid receptor affinity than the parent compound — blocking pain signal transmission [4][5]. (2) The (+) enantiomer inhibits serotonin reuptake while the (−) enantiomer inhibits norepinephrine reuptake, mimicking the action of SNRI antidepressants and amplifying descending pain-inhibition pathways [2][6]. This dual action makes tramadol pharmacologically distinct from conventional opioids; notably, the opioid antagonist naloxone only partially reverses its effects [5][7].
Risks & side effects
Most important: Tramadol carries an FDA boxed warning for serious, life-threatening, or fatal respiratory depression — particularly when doses are started, increased, or taken with CNS depressants such as benzodiazepines or alcohol [8][3]. Unlike most opioids, it also uniquely lowers the seizure threshold and can cause serotonin syndrome, especially when combined with SSRIs, SNRIs, MAOIs, or tricyclic antidepressants — creating additional life-threatening risks not present with other opioids [6][7].
Common
Serious
- Respiratory depression — life-threatening slowing or stopping of breathing, especially on initiation, dose increase, or with CNS depressants [8][3]
- Seizures — risk estimated at 0.5–1% at therapeutic doses, substantially higher with dose escalation or seizure-lowering co-medications [6][7]
- Serotonin syndrome — potentially fatal hyperthermia, agitation, rigidity, and tachycardia when combined with serotonergic drugs [6][7]
- Physical dependence and withdrawal — abrupt cessation causes anxiety, sweating, insomnia, tremors, diarrhea, and rarely hallucinations [4][8]
- Addiction and misuse — opioid use disorder is possible even when taken as directed [8][9]
- Neonatal opioid withdrawal syndrome — regular use in pregnancy causes life-threatening withdrawal in newborns [3]
Safety & harm reduction
- Children under 12 years of age [8]
- Children under 18 years following tonsillectomy or adenoidectomy [8]
- Patients with a current or recent (within 14 days) MAOI use — risk of fatal serotonin syndrome [7][6]
- Patients with severe respiratory depression or unmonitored airway obstruction [8]
- Patients who are suicidal or addiction-prone — prescribing guidance explicitly contraindicates this [4]
- Pregnant women (regular use) — causes neonatal opioid withdrawal syndrome [3]
- Breastfeeding mothers who are ultra-rapid CYP2D6 metabolizers — can cause fatal infant overdose [8]
- Respiratory rate and oxygen saturation — especially on initiation or dose changes [8]
- Signs of serotonin syndrome (agitation, hyperthermia, tremor, tachycardia) when co-administered with serotonergic agents [6][7]
- Seizure activity — baseline seizure history must be assessed; caution in epilepsy [7]
- Renal and hepatic function — half-life approximately doubles with impairment; dose adjustment required [5]
- CYP2D6 metabolizer status — ultra-rapid metabolizers face toxicity risk; poor metabolizers may get reduced benefit [5][8]
- Signs of dependence, misuse, or opioid use disorder [9]
- MAOIs (e.g. phenelzine, selegiline) — contraindicated; risk of fatal serotonin syndrome or seizure [6][7]
- SSRIs / SNRIs / TCAs / triptans — significant serotonin syndrome risk; avoid combination or monitor intensively [6][7]
- Benzodiazepines, other opioids, CNS depressants, alcohol, gabapentinoids — additive CNS/respiratory depression, coma, death [8][3]
- CYP3A4 inhibitors (e.g. ketoconazole, erythromycin) — increase tramadol exposure; higher toxicity risk [2][7]
- CYP2D6 inhibitors (e.g. fluoxetine, paroxetine) — reduce M1 metabolite formation, reducing efficacy but potentially altering serotonin risk [5]
- Carbamazepine and other CYP inducers — lower tramadol levels and may reduce analgesia [7]
- Naloxone in overdose — may paradoxically increase seizure risk [4]
- Start at the lowest effective dose (commonly 25–50 mg IR) and titrate slowly to reduce adverse-event risk [1][3]
- Do not exceed 400 mg/day (total); do not exceed the single-dose limit — exceeding recommendations risks respiratory depression, seizures, and death [2]
- Do not crush, chew, or break extended-release formulations — causes rapid release and overdose risk [3]
- Taper dose gradually over several weeks rather than stopping abruptly to prevent severe withdrawal [4][3]
- Have naloxone (or nalmefene) accessible for emergency reversal of opioid overdose [8]
- Avoid all alcohol and CNS depressants during use [8][3]
- Inform all treating clinicians (including dentists and surgeons) of tramadol use before any procedure [8]
Dosage context
Tramadol dosing information below is commonly reported in prescribing references and is NOT a personal prescription. Immediate-release: typically 25–50 mg orally every 4–6 hours; maximum 400 mg/day in adults under 75 years [1][2]. Extended-release: 100–300 mg once daily, maximum 300 mg/day [4]. Dose reductions are required in renal impairment (CrCl <30 mL/min) and hepatic impairment, where half-life approximately doubles [5]. Titration is strongly advised — sources recommend starting at 25 mg/day and increasing by 25–50 mg every 3 days [1].
Sources
- 1.DrugBank — Tramadol
- 2.USPTO Patent — Tramadol Dual Mechanism (10646433)
- 3.MedlinePlus — Tramadol Drug Information
- 4.FDA Label — ULTRAM (tramadol HCl) 2017
- 5.USPTO Patent — Tramadol Pharmacokinetics (10729645)
- 6.Medsafe NZ — Serious Reactions with Tramadol: Seizures and Serotonin Syndrome
- 7.Drugs.com — Tramadol Uses, Side Effects, Dosage & Warnings
- 8.Healthline — Tramadol Oral Tablet
- 9.American Addiction Centers — Tramadol Addiction and Abuse
- 10.FDA Label — Tramadol HCl Extended-Release (2010)
- 11.StatPearls / NCBI Bookshelf — Tramadol
- 12.DailyMed NIH — Tramadol Hydrochloride Tablet
- 13.EZCalculator — Tramadol Dosage Guide
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.